On Friday, Midcap stock jumped by 18.4 percent after its net profits increased by 244 percent on a YoY basis.
With a market capitalization of ₹18,394.58 crores, Natco Pharma Ltd stock rose by 18.4 percent from its previous closing price of ₹887.10 to the a new 52 week high of ₹1,051 and closed at ₹1,015.60
It has seen an increase of 18.62 percent returns in six months and 89.89 percent returns in one year.
The YoY revenue from operations increased by 54 percent from ₹492.5 crores in Q3 FY23 to ₹758.6 crores in Q3 FY24, and in the same period, the net profits rose by 244 percent from ₹62.3 crores to ₹212.7 crores.
On the other hand, QoQ revenue from operations decreased by 26.38 percent from ₹1,031.4 crores in Q2 FY24 to ₹758.6 crores in Q3 FY24, and in the same period, net profits also declined by 42.27 percent from ₹369 crores to ₹212.7 crores.
It has a return on equity of 15.66 percent, a return on capital employed of 17.70 percent, and a net profit margin of 26.42 percent.
According to the FY23 annual reports, the company has expressed its plans, with a target of launching 8–10 products in the next two years and registering niche molecules for both domestic and international markets.
The company has a global presence in the USA, Brazil, Canada, Indonesia, and Colombia and operates in two distinct business segments, pharmaceuticals and agrochemicals.
The pharmaceutical segment, an established business, plays a vital role in the company’s revenue generation. This segment comprises two key components: finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs). The API business holds a strategic position, fulfilling both the internal demand for essential molecules and direct sales to customers.
The shareholder pattern of the company is 49.71 percent held by the promoters, followed by 23.48 percent held by the public, the remaining 13.99 percent held by domestic institutional investors (DII), and 12.82 percent by foreign institutional investors (FII).
Natco Pharma is an Indian pharmaceutical company based in Hyderabad, Telangana, that is a major producer of oncology medicines. Founded in 1981
Written by Praveen R
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
